2026 International Congress Archives - Page 162 of 208

Real-World Experience with Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) in Advanced Parkinson’s Disease: A Single-Centre Cohort Study

K. Waqar, M. Thomas, Y. Abdelmajid, E. Freitas, R. Cabrito, RH. Battah, A. Anjum, SH. Mittal (Abu Dhabi, United Arab Emirates)
Real-World Impact of “Off” Time Reduction with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of the ROSSINI Study

W. Jost, T. Henriksen, S. Hassin-Baer, R. Hauser, L. Bergmann, M. O'Meara, S. Pan, J. Parra, M. Shah, J. Aldred (Wolfach, Germany)
Real-World Mobile Voice Classification for Parkinson’s Disease Using Convolutional Neural Networks and Mel-Spectrogram Features

N. Leabthong, J. Sringean, T. Laosombut, N. Jeh-Voh1, Z. Win, P. Rattanajun, S. Phumphid, C. Anan, J. Meesri, S. Wekhinhiran, O. Phokaewvarangkul, P. Panyakaew, S. Maytharakcheep, P. Jagota, R. Bhidayasiri (Bangkok, Thailand)
Real-World Mobility Measures Reveal Early Indicators of Parkinson’s Disease Risk in Older Women

Y. Udi, P. Wayne, IM. Lee, P. Rist, A. Salomon, E. Gazit, J. Hausdorff, R. Gilad-Bachrach (Tel Aviv, Israel)
Real-World Outcomes with Directional Deep Brain Stimulation Systems Featuring Multiple Independent Current Control: U.S. Experience

M. Okun, K. Foote, T. Zesiewicz, Y. Bezchlibnyk, A. Papanastassiou, O. Vaou, J. Carlson, J. Aldred, V. Krishna, B. Dalm, C. Luca, J. Jagid, J. Durphy, J. Pilitsis, L. Verhagen Metman, S. Sani, D. Kern, S. Ojemann, R. Shivacharan, E. Goldberg (Gainesville, USA)
Real-World Relationship Between Beta-Band LFP Activity and Motor States in Parkinson’s Disease

IMV. Martin, DRM. Rodriguez-Martin, SM. Marco, BT. Tijero, TF. Fernández, RDP. Del Pino, MA. Acera, JCG. Gómez-Esteban, MRL. Ruiz-López (Cornellà de Llobregat, Spain)
Real-World Survival, Healthcare Access, and Medication Patterns in Atypical Parkinsonian Disorders: A Multi-System EHR Analysis

J. Fenn, N. Mcfarland (Gainesville, USA)
Real-World Turning Impairments in Fallers with Parkinson’s Disease

V. Shah, R. Baudier, C. Silva-Batista, A. Ragothaman, P. Carlson-Kuhta, J. Lapidus, F. Horak, M. Mancini (Portland, USA)
Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort

I. Murasan, R. Margarit, R. Radu, L. Ungureanu, S. Berzunteanu, A. Drujescu, D. Batrinu, R. Chiujdea, R. Ilea, S. Diaconu, C. Falup-Pecurariu (Brasov, Romania)
Reasons and Factors Influencing Parkinson’s Patients’ Decision to Decline Deep Brain Stimulation

L. Cabrera, H. King, L. Al Damluji, J. Blumenthal-Barby, B. Levi, S. de Jesus (University Park, USA)